Pre-Made Citatuzumab Bogatox biosimilar, Fusion Protein, Citatuzumab-Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody fused with Bougainvillea spectabilis Willd bouganin for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-781

Pre-Made Citatuzumab Bogatox biosimilar, Fusion Protein, Citatuzumab-Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody fused with Bougainvillea spectabilis Willd bouganin is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Citatuzumab bogatox (VB6-845) is a monoclonal antibody Fab fragment fused with bouganin, a ribosome inactivating protein from the plant Bougainvillea spectabilis.[1] It has undergone preclinical development for the treatment of ovarian cancer and other solid tumors.[2]

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-781-1mg 1mg 3090
GMP-Bios-INN-781-10mg 10mg Inquiry
GMP-Bios-INN-781-100mg 100mg Inquiry
GMP-Bios-INN-781-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Citatuzumab Bogatox biosimilar, Fusion Protein, Citatuzumab-Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody fused with Bougainvillea spectabilis Willd bouganin
INN Name Citatuzumab Bogatox
TargetEPCAM
FormatFusion Protein
DerivationHumanized
Species Reactivityhuman
CH1 IsotypeFab - G1 - kappa
VD LCFab - G1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesViventia Biotechnologies Inc. (Mississauga ON Canada)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0